Steven Bloom is the Chief Business Officer of Vincerx. Mr Bloom is a seasoned executive with 35 years of experience in the healthcare industry. Prior to joining Vincerx Pharma, he held senior roles at Eli Lilly and Company, overseeing marketing, patient advocacy, and corporate affairs. He also helped build and scale startups like Inflexxion and Pharmetrics before the latter was acquired by IMS Health. Mr Bloom led business development activities at ZIOPHARM Oncology and served as Chief Strategy Officer at VERASTEM Oncology, playing a key role in acquiring duvelisib, which was approved by the FDA in September 2018 for the treatment of CLL and FL. He also served as Chief Business Officer at Boston Pharmaceuticals and, most recently, at Transgene. Mr. Bloom graduated from Northeastern University College of Pharmacy in 1984 and has been an American Cancer Society Road to Recovery driver since 2008. Steve is currently Chairman of the Board of Directors of the CLL Society.